Two patients complained of severe abdominal pain as the first sign of varicella zoster virus infection about 1 year after allogeneic BMT. In case 1, eruptions, found on the face and chest on admission, became vesicular and dispersed on the third hospital day. Though acyclovir (ACV) was immediately started, he died on the fourth day. In case 2, skin rash was never observed during the clinical course. Laparotomy on the third hospital day revealed many hemorrhagic spots on the liver surface and mucous membrane of the upper GI tract, indicating disseminated visceral disease. Empiric therapy with ACV was successful. Bone Marrow Transplantation (2000) 25, 1003-1005. Keywords: BMT; VZV; acute abdomen; ACV; empiric therapy Varicella zoster virus (VZV) infection is a frequent complication of allogeneic bone marrow transplantation (BMT), and sometimes proves fatal.
Varicella zoster virus (VZV) infection is a frequent complication of allogeneic bone marrow transplantation (BMT), and sometimes proves fatal. 1 Acute abdominal pain as a presenting symptom of VZV infection has been reported among recipients of allogeneic BMT. Difficulty in diagnosing in this setting has resulted in a high rate of fatal outcomes. [2] [3] [4] [5] [6] Although some authors of these reports have emphasized that suspicion of the presence of visceral VZV infection is important, diagnosis is difficult when abdominal symptoms precede characteristic skin eruptions or no skin eruptions appear.
Here, we report two patients with VZV infection after allogeneic BMT who complained of severe acute abdominal pain as the first clinical sign. In the second case, laparotomy and endoscopy revealed disseminated visceral disease, and empiric therapy with acyclovir (ACV) was successful even though no skin eruptions appeared during the clinical course. 
Case reports

Patient 1
A 30-year-old male recipient of HLA-matched sibling marrow was admitted for acute epigastric and back pain 320 days post-BMT. The patient had been diagnosed with chronic myelogenous leukemia in August 1991, and underwent transplantation. Although his donor had a history of varicella, he was not tested for VZV antibody. The recipient's VZV antibody status as measured by complement fixation (CF) was negative before transplantation. His post-transplant course was complicated by progressive chronic graft-versus-host disease (GVHD) of the liver and oral mucosa that was treated with prednisolone. He developed hemorrhagic cystitis 209 days post-BMT that caused renal failure, and continuous ambulatory peritoneal dialysis was required for a few months. Five days before admission, he suffered progressive epigastric pain radiating to the back, and 2 days later he found eruptions on his face and chest. Prior to the onset of abdominal pain, he had no known exposure to VZV. Results of gastroscopy performed in another hospital were normal. Physical examination on admission revealed papules on the face and trunk. He had a slight fever and severe epigastric tenderness without rigidity. He complained of severe back pain which was enhanced in the standing position. Laboratory studies revealed WBC 8.2 ϫ 10 9 /l, Hb 12.9 g/dl, and platelet count 149 ϫ 10 9 /l. Total bilirubin, creatinine and blood urea nitrogen (BUN) were in the normal range (NR). Serum amylase was 152 U/l (NR 50-145), Alanine aminotransferase (ALT) was 212 U/l (NR р 35), aspartate aminotransferase (AST) 262 U/l (NR р 38), and alkaline phosphatase 152 U/l (NR 25-120). Abdominal ultrasound examination and CT scan results were normal. One day after admission, the pain grew progressively worse, and neither buprenorphine hydrochloride nor morphine sulfate were effective. On the third hospital day, the patient's rash became vesicular and widely dispersed over his entire body. Varicella was then diagnosed and anti-viral therapy with ACV (10 mg/kg three times daily i.v.) was started. However, he developed hypotension and renal failure and died the day after diagnosis.
Patient 2
A 32-year-old male recipient of HLA-matched sibling marrow was admitted for acute epigastric pain 356 days post-BMT. He was transplanted during first complete remission of acute lymphoblastic leukemia. Neither donor nor recipient had a history of varicella, and their VZV antibody status as measured by CF was negative before transplantation. He developed acute GVHD (grade 1) and Pneumocystis carinii pneumonia as complications. Because bronchiolitis obliterans organizing pneumonia and chronic GVHD (liver and joints) developed at days 183 and days 243 respectively, he took cyclosporin A (75 mg/day) and prednisolone (25 mg/day) at admission. On admission, he had a 4-day history of progressive epigastric pain. He recalled no contact with patients infected with VZV prior to the onset of abdominal pain. Physical examination revealed moderate epigastric tenderness without rigidity or rebound tenderness. Bowel sounds were hyperactive but not metallic. He had a slight fever and no skin eruptions. No coagulation abnormalities were identified. Chest X-ray was normal, and abdominal ultrasound, CT scan and gastroscopy were not diagnostic. Scopolamine butylbromide and pentazocine were not effective for the pain. On the third hospital day, the tenderness became severe in the upper abdomen with muscle guarding. He developed thrombocytopenia (platelet count 30 ϫ 10 9 /l). ALT rose to 384 U/l, and total bilirubin was 1.8 mg/dl. Laparotomy revealed spotty hemorrhage on the liver surface and massive intestinal bleeding. Endoscopic examination during operation revealed hemorrhagic erosions in the lower esophagus, stomach and jejunum. On the basis of these observations, viral infection was suspected and antiviral therapy with ACV (16 mg/kg/day) was started on the first postoperative day. The patient subsequently improved markedly. Although there was no skin rash during the clinical course, we confirmed VZV infection after surgery by the presence of specific IgM antibody and increase in specific IgG antibody (level of IgG antibody increased eight times in 16 days) as measured by enzyme-linked immunosorbent assay. The patient's serum was VZV polymerase chain reaction (PCR)-positive on the fourth postoperative day, even on ACV therapy.
Discussion
We report two cases of visceral VZV infection late after allogeneic BMT with acute abdominal pain as a presenting symptom. To our knowledge, an abdominal manifestation has been reported as one of the first clinical signs of VZV infection after allogeneic BMT in nine cases including the two presented here. [2] [3] [4] [5] [6] Among the seven patients who received ACV, five recovered from VZV infection, yielding a mortality rate of 28.6%. Both of the remaining two patients, who did not receive ACV, died of visceral VZV infection with a mortality rate of 100%. As already noted, clinical suspicion of abdominal presentation of VZV infection is important because of the availability of non-toxic and effective anti-viral therapy with ACV.
Of the nine cases, seven presented with skin lesions suggestive of VZV infection after or concomitantly with the first abdominal symptom. These skin manifestations led to initiation of ACV. The remaining two patients had no skin manifestations of VZV infection over their entire clinical course. One autopsy case was diagnosed using PCR from ante-mortem serum and liver obtained at necropsy, 5 the author suggested that PCR of peripheral blood samples might be useful for early diagnosis. Though a PCR method for blood samples may be the fastest among diagnostic tests for VZV dissemination, clinical suspicion of the disease is essential for the diagnostic PCR method to be used. The other case, one of ours, was suspected of having a disseminated abdominal disease at laparotomy and endoscopy, and recovered with empiric ACV treatment. In our case, we confirmed VZV infection by the presence of specific IgM antibody, increase in IgG antibody, and positive PCR results. If we had performed these tests early enough, the laparotomy would not have been necessary. We believe that such tests should be performed immediately, when recipients complain of severe abdominal pain. If the general condition is too serious to wait for these results, ACV should be started empirically.
Rogers et al 5 noted in their report that they introduced the policy of coadministering prophylactic oral ACV to all post-BMT patients given steroids, since viral dissemination may be promoted by immune suppression associated with both the GVHD itself and the use of steroid treatment. 7 Though ACV prophylaxis was shown to be effective for preventing recurrent VZV infection in BMT recipients, 8 prolonged administration of ACV may result in resistance of VZV strains to ACV. Varicella-zoster immune globulin (VZIG) is indicated for prophylaxis of primary VZV infection in susceptible, VZV-seronegative high-risk patients, including BMT recipients. To be effective, it must be administered within 96 h after exposure to VZV. Exposure to VZV prior to abdominal symptoms was not evident in our two patients, nor was it described in other reported cases. Live varicella vaccine may be inappropriate for BMT recipients since it contains infectious virus. It is unclear whether inactivated varicella vaccine results in immunological enhancement strong enough to prevent VZV dissemination.
The occurrence of abdominal pain as one of the earliest signs of VZV infection has been reported in immunocompromised hosts other than recipients of allogeneic BMT. These include recipients of autologous BMT, 4 patients with leukemia, 9 and a patient with AIDS. 10 In these patients, clinical suspicion of abdominal presentation of VZV also merits initiation of ACV treatment, in view of its mortality rate.
